ClinicalTrials.gg
CompletedNCT01909934Updated Sep 19, 2025Results posted

Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

A Phase 4 interventional study of Brentuximab vedotin in Lymphoma, sponsored by Takeda. Completed at 40 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-19.

Primary conditionLymphoma, Large-Cell, AnaplasticRegistry: LymphomaReclassifiedWhy we changed it
Registry
Lymphoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Large-Cell, Anaplastic
Why
  1. The study's title name Lymphoma, Large-Cell, Anaplastic, a narrower term within Lymphoma.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic — 1 open to participants now, 2 under way, none of them phase 3. Brentuximab Vedotin · Lymphoma, Large-Cell, Anaplastic.

Enrollment
8th of 21
50 · median 44
Started
2014
the only one that year
Phase 4
Only one
of the 21
Registered
12th of 21
by date
Lead sponsor
2 of 21
Takeda

Among the 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic, this one is the 8th largest by enrollment, is the only one that started in 2014, is the only one in phase 4, and was the 12th registered.

Lymphoma, Large-Cell, Anaplastic

397 studies on the registry are indexed under Lymphoma, Large-Cell, Anaplastic; 26 are open to participants now.

Browse Lymphoma, Large-Cell, Anaplastic studies →

Open to participants now

1 of the 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 21 Lymphoma, Large-Cell, Anaplastic studies recruiting now, 12 (57%) set no upper age limit and 6 (29%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic, or all of them as a file.
02

Study summary

The purpose of this study is to assess the antitumor efficacy of single-agent brentuximab vedotin 1.8 mg/kg administered intravenously (IV) every 3 weeks, as measured by the overall objective response rate (ORR) in patients with r/r sALCL following at least 1 multiagent chemotherapy regimen (cyclophosphamide, doxorubicin hydrochloride [hydroxydaunorubicin], vincristine sulfate [Oncovin], and prednisone [CHOP] or equivalent multiagent chemotherapy regimens with curative intent).

03

Conditions studied

  • Lymphoma

Keywords

  • Lymphoma
  • Anaplastic Large-cell
  • Relapsed
  • Refractory
  • Antigens, CD30
  • Antibody-Drug Conjugate
  • Antibodies, Monoclonal
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Large-Cell, Anaplastic
  • monomethyl auristatin E
  • Drug Therapy
  • Immunotherapy
  • Hematologic Diseases
04

In context

Lymphoma, Large-Cell, Anaplastic Reclassified

397 studies on the registry are indexed under Lymphoma, Large-Cell, Anaplastic; 26 are open to participants now.

This study's enrollment of 50 is above the median of 37 across 306 interventional studies indexed under Lymphoma, Large-Cell, Anaplastic.

Browse Lymphoma, Large-Cell, Anaplastic studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Compared within Lymphoma, Large-Cell, Anaplastic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants age 18 years or older, with sALCL who have previously received at least 1 multiagent chemotherapy
  • Bidimensional
  • An (ECOG) performance status of 0 or 1
  • Female participants who are for at least 1 year before the screening visit, surgically sterile, or agree to practice 2 effective methods of , at the same time, from the time of signing the form through 30 days after the last dose of study drug, or agree to practice true abstinence
  • Male participants who agree to practice effective barrier contraception during the entire study treatment period through 6 months after the last dose of study drug or agree to practice true abstinence
  • Clinical laboratory values as specified in the study protocol

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with brentuximab vedotin.
  • Previously received an transplant.
  • Participants with current diagnosis of primary cutaneous anaplastic large cell lymphoma [ALCL] (participants whose ALCL has transformed to sALCL are eligible).
  • Known cerebral/meningeal disease including signs or symptoms of progressive multifocal leukoencephalopathy (PML)
  • Female participants who are lactating and breastfeeding or pregnant
  • Known (HIV) positive
  • Known surface antigen-positive, or known or suspected active infection
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Brentuximab Vedotin 1.8 mg/kg

    Participants received brentuximab vedotin 1.8 mg/kg as a 30 minute intravenous (IV) infusion on Day 1 of each 3 week cycle. Participants with stable disease or better and without unacceptable toxicity were to receive a minimum of 8 cycles with the opportunity to receive a maximum of 16 cycles.

    Drug: Brentuximab vedotin

Interventions

07

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with a complete remission (CR) or partial remission (PR) by Independent Review Facility (IRF) response assessment according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.

    Time frame: Up to data cut-off date: 04 May 2021 (Up to approximately 7 years)

Secondary outcomes

  1. Duration of Response (DOR) Per IRF

    DOR was defined as the time between initial response and documented tumor progression in the subset of participants who achieved an objective response, either CR or PR. DOR per IRF was based upon the radiological assessment of measured lesions from an independent review facility. DOR was censored on the date of the last disease assessment documenting absence of progressive disease (PD) for participants who were lost to follow-up, withdrew consent, started a new anticancer therapy other than stem cell transplant (SCT), or discontinued treatment due to undocumented PD after the last adequate disease assessment.

    Time frame: Until disease progression, death, or the data cut-off date: 4 May 2021 (Up to approximately 7 years)

  2. Progression-free Survival (PFS) Per IRF

    PFS is defined as the time from start of study treatment to first documentation of objective tumor progression or to death due to any cause, whichever comes first. PFS per IRF is based upon the radiological assessment from an independent review facility.

    Time frame: Until disease progression, death, or the data cut-off date: 4 May 2021 (Up to approximately 7 years)

  3. Complete Remission Rate (CRR) Per IRF

    CRR is defined as percentage of participants with CR. CR is defined as the disappearance of all evidence of disease.

    Time frame: Until disease progression, death, or the data cut-off date: 4 May 2021 (Up to approximately 7 years)

  4. Overall Survival (OS)

    OS is defined as the time from start of study treatment to date of death due to any cause.

    Time frame: Until disease progression, death, or end of study (Up to approximately 10.7 years)

  5. Percentage of Participants Receiving Hematopoietic Stem Cell Transplant (SCT) Following Treatment With Brentuximab Vedotin

    Time frame: Until disease progression, death, or end of study (Up to approximately 10.7 years)

  6. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs by Severity (Grade 3 or Higher)

    An adverse event (AE): any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to medicinal product. TEAE was defined as any AE that started after the first administration of study drug in this continuation study. Serious TEAEs: defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect, or is a medically important event.

    Time frame: From first dose up to 30 days post last dose of study drug (Up to approximately 1 year)

  7. Concentration of Serum Antibody-drug Conjugate (ADC) at the End of Infusion

    Time frame: Cycle 1, Day 1 and Cycle 3, Day 1 at the end of infusion

  8. Concentration of Serum Total Antibody (TAb) Conjugate Plus Free Total Antibody

    Time frame: Cycle 1, Day 1 and Cycle 3, Day 1 at the end of infusion

  9. Maximum Concentration for Unconjugated Drug- Monomethyl Auristatin E (MMAE)

    Time frame: Cycle 1, Day 1 and Cycle 3, Day 1 at the end of infusion

  10. Percentage of Participants With Presence of Anti-Therapeutic Antibodies (ATA) and Neutralizing Antibodies (NAb) to Brentuximab Vedotin

    Time frame: Up to 16 cycles (each cycle = 21 days)

08

Results

Posted May 26, 2022

Participant flow

Participants took part in the study at various investigative sites globally from 23 January 2014 to 29 August 2024.

Participant flow — Overall Study
MilestoneBrentuximab Vedotin 1.8 mg/kg
Started50
Completed19
Not completed31
Withdrew: Withdrawal by subject3
Withdrew: Lost to follow-up1
Withdrew: Death25
Withdrew: Withdrawal of informed consent1
Withdrew: Reason not specified1

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants with a complete remission (CR) or partial remission (PR) by Independent Review Facility (IRF) response assessment according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites.

Time frame:
Up to data cut-off date: 04 May 2021 (Up to approximately 7 years)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsBrentuximab Vedotin 1.8 mg/kg
Objective Response Rate (ORR)64 (49 to 77)
SecondaryDuration of Response (DOR) Per IRF

DOR was defined as the time between initial response and documented tumor progression in the subset of participants who achieved an objective response, either CR or PR. DOR per IRF was based upon the radiological assessment of measured lesions from an independent review facility. DOR was censored on the date of the last disease assessment documenting absence of progressive disease (PD) for participants who were lost to follow-up, withdrew consent, started a new anticancer therapy other than stem cell transplant (SCT), or discontinued treatment due to undocumented PD after the last adequate disease assessment.

Time frame:
Until disease progression, death, or the data cut-off date: 4 May 2021 (Up to approximately 7 years)
Reported as:
Median · months
Duration of Response (DOR) Per IRF
monthsBrentuximab Vedotin 1.8 mg/kg
Duration of Response (DOR) Per IRFNA (19.71 to NA)
SecondaryProgression-free Survival (PFS) Per IRF

PFS is defined as the time from start of study treatment to first documentation of objective tumor progression or to death due to any cause, whichever comes first. PFS per IRF is based upon the radiological assessment from an independent review facility.

Time frame:
Until disease progression, death, or the data cut-off date: 4 May 2021 (Up to approximately 7 years)
Reported as:
Median · months
Progression-free Survival (PFS) Per IRF
monthsBrentuximab Vedotin 1.8 mg/kg
Progression-free Survival (PFS) Per IRF20.9 (4.17 to NA)
SecondaryComplete Remission Rate (CRR) Per IRF

CRR is defined as percentage of participants with CR. CR is defined as the disappearance of all evidence of disease.

Time frame:
Until disease progression, death, or the data cut-off date: 4 May 2021 (Up to approximately 7 years)
Reported as:
Number · percentage of participants
Complete Remission Rate (CRR) Per IRF
percentage of participantsBrentuximab Vedotin 1.8 mg/kg
Complete Remission Rate (CRR) Per IRF30 (18 to 45)
SecondaryOverall Survival (OS)

OS is defined as the time from start of study treatment to date of death due to any cause.

Time frame:
Until disease progression, death, or end of study (Up to approximately 10.7 years)
Reported as:
Median · months
Overall Survival (OS)
monthsBrentuximab Vedotin 1.8 mg/kg
Overall Survival (OS)67.6 (17.68 to NA)
SecondaryPercentage of Participants Receiving Hematopoietic Stem Cell Transplant (SCT) Following Treatment With Brentuximab Vedotin
Time frame:
Until disease progression, death, or end of study (Up to approximately 10.7 years)
Reported as:
Number · percentage of participants
Percentage of Participants Receiving Hematopoietic Stem Cell Transplant (SCT) Following Treatment With Brentuximab Vedotin
percentage of participantsBrentuximab Vedotin 1.8 mg/kg
Percentage of Participants Receiving Hematopoietic Stem Cell Transplant (SCT) Following Treatment With Brentuximab Vedotin28
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs by Severity (Grade 3 or Higher)

An adverse event (AE): any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to medicinal product. TEAE was defined as any AE that started after the first administration of study drug in this continuation study. Serious TEAEs: defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect, or is a medically important event.

Time frame:
From first dose up to 30 days post last dose of study drug (Up to approximately 1 year)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs by Severity (Grade 3 or Higher)
percentage of participantsBrentuximab Vedotin 1.8 mg/kg
TEAEs94
Serious TEAEs32
Drug-Related TEAEs70
TEAEs by Severity (Grade 3 or Higher)58
SecondaryConcentration of Serum Antibody-drug Conjugate (ADC) at the End of Infusion
Time frame:
Cycle 1, Day 1 and Cycle 3, Day 1 at the end of infusion
Reported as:
Geometric mean · micrograms per liter (µg/L)
Concentration of Serum Antibody-drug Conjugate (ADC) at the End of Infusion
micrograms per liter (µg/L)Brentuximab Vedotin 1.8 mg/kg
Cycle 1, Day 135 ± 35
Cycle 3, Day 138 ± 25
SecondaryConcentration of Serum Total Antibody (TAb) Conjugate Plus Free Total Antibody
Time frame:
Cycle 1, Day 1 and Cycle 3, Day 1 at the end of infusion
Reported as:
Geometric mean · µg/L
Concentration of Serum Total Antibody (TAb) Conjugate Plus Free Total Antibody
µg/LBrentuximab Vedotin 1.8 mg/kg
Cycle 1, Day 133 ± 29
Cycle 3, Day 138 ± 23
SecondaryMaximum Concentration for Unconjugated Drug- Monomethyl Auristatin E (MMAE)
Time frame:
Cycle 1, Day 1 and Cycle 3, Day 1 at the end of infusion
Reported as:
Geometric mean · nanogram per milliliter (ng/ml)
Maximum Concentration for Unconjugated Drug- Monomethyl Auristatin E (MMAE)
nanogram per milliliter (ng/ml)Brentuximab Vedotin 1.8 mg/kg
Cycle 1, Day 10.25 ± 87
Cycle 3, Day 10.29 ± 88
SecondaryPercentage of Participants With Presence of Anti-Therapeutic Antibodies (ATA) and Neutralizing Antibodies (NAb) to Brentuximab Vedotin
Time frame:
Up to 16 cycles (each cycle = 21 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Presence of Anti-Therapeutic Antibodies (ATA) and Neutralizing Antibodies (NAb) to Brentuximab Vedotin
percentage of participantsBrentuximab Vedotin 1.8 mg/kg
ATA Positive30
Neutralizing ATA Positive0.0

Adverse events

Collected over All-cause mortality: Throughout the study (Up to approximately 10.7 years); Serious and other adverse events: From first dose up to 30 days post last dose of study drug (up to approximately 1 year). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brentuximab Vedotin 1.8 mg/kg25/50 (50%)16/50 (32%)37/50 (74%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventBrentuximab Vedotin 1.8 mg/kg
Anaplastic large cell lymphoma T- and null-cell typesNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/50
DiarrhoeaGastrointestinal disorders2/50
DyspnoeaRespiratory, thoracic and mediastinal disorders2/50
General physical health deteriorationGeneral disorders2/50
HypotensionVascular disorders2/50
PneumoniaInfections and infestations2/50
Abdominal incarcerated herniaGastrointestinal disorders1/50
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/50
Aortic stenosisVascular disorders1/50
Autonomic neuropathyNervous system disorders1/50
Most frequent other events
Showing 10 of 23
Most frequent other events
EventBrentuximab Vedotin 1.8 mg/kg
Peripheral sensory neuropathyNervous system disorders9/50
PyrexiaGeneral disorders9/50
DiarrhoeaGastrointestinal disorders8/50
NeutropeniaBlood and lymphatic system disorders8/50
AnaemiaBlood and lymphatic system disorders7/50
FatigueGeneral disorders6/50
ArthralgiaMusculoskeletal and connective tissue disorders5/50
NauseaGastrointestinal disorders5/50
Back painMusculoskeletal and connective tissue disorders4/50
ConstipationGastrointestinal disorders4/50

Baseline characteristics

Safety Population included all participants who received at least 1 dose of brentuximab vedotin.

Age, Continuous
Age, Continuous(years)Brentuximab Vedotin 1.8 mg/kg
Mean56.4 ± 16.70
Sex: Female, Male
Sex: Female, Male(Participants)Brentuximab Vedotin 1.8 mg/kg
Female31
Male19
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Brentuximab Vedotin 1.8 mg/kg
Hispanic or Latino2
Not Hispanic or Latino45
Unknown or Not Reported3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Brentuximab Vedotin 1.8 mg/kg
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White50
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Brentuximab Vedotin 1.8 mg/kg
Belgium1
Croatia2
Czech Republic12
Hungary5
Poland8
Portugal3
Romania3
Spain4
Turkey6
United Kingdom6
Height
Height(centimeters (cm))Brentuximab Vedotin 1.8 mg/kg
Mean166.8 ± 10.40
Weight
Weight(kilograms (kg))Brentuximab Vedotin 1.8 mg/kg
Mean75.2 ± 20.73
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per meter squared (kg/m^2))Brentuximab Vedotin 1.8 mg/kg
Mean26.9 ± 6.39
09

Study locations

40 sites
  • ZNA Stuivenberg
    Antwerp, 2060, Belgium
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Clinical Hospital Centre Rijeka
    Rijeka, 51000, Croatia
  • Clinical Hospital Centre Zagreb
    Zagreb, 10000, Croatia
  • Clinical Hospital Dubrava
    Zagreb, 10000, Croatia
  • Fakultni nemocnice Brno
    Brno, 625 00, Czechia
  • Fakultni nemocnice Olomouc
    Olomouc, 779 00, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Prague, 100 34, Czechia
  • Vseobecna fakultni nemocnice v Praze
    Prague, 128 08, Czechia
  • Semmelweis Egyetem
    Budapest, 1083, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Pecsi Tudomanyegyetem
    Pécs, 7624, Hungary
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-952, Poland
  • Malopolskie Centrum Medyczne s.c.
    Krakow, 30-510, Poland
  • SPZOZ MSW zWarminsko-MazurskimCen.Onko.wOlsztynie
    Olsztyn, 10-228, Poland
  • Centrum Onkologii-Instytut im. M. Sklodowskiej Curie
    Warsaw, 02-781, Poland
  • Hospital de Braga
    Braga, 4710-243, Portugal
  • Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria
    Lisbon, 1649-035, Portugal
  • Centro Hospitalar do Porto, E.P.E. - Hospital de Santo Antonio
    Porto, 4099-001, Portugal
  • Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE
    Porto, 4200-072, Portugal
  • Policlinica de Diagnostic Rapid SA
    Brasov, 500152, Romania
  • Spitalul Clinic Colentina
    Bucharest, 020125, Romania
  • Spitalul Clinic Coltea
    Bucharest, 030171, Romania
  • Spitalul Clinic Judetean de Urgenta Targu Mures
    Târgu Mureş, 540042, Romania
  • ICO lHospitalet Hospital Duran i Reynals
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, Cantabria 39008, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Ankara University Medical Faculty
    Ankara, 06340, Turkey (Türkiye)
  • Pamukkale Uni. Med. Fac.
    Denizli, 20070, Turkey (Türkiye)
  • Istanbul Bilim University Medical Fac.
    Istanbul, 34200, Turkey (Türkiye)
  • Ege University Medical Faculty
    Izmir, 35040, Turkey (Türkiye)
  • Dokuz Eylul University Faculty of Medicine
    Izmir, 35340, Turkey (Türkiye)
  • Erciyes University Medical Faculty
    Kayseri, 38039, Turkey (Türkiye)
  • Royal Cornwall Hospital
    Truro, Cornwall TR1 3LJ, United Kingdom
  • The Christie
    Manchester, Greater Manchester M20 4BX, United Kingdom
  • Birmingham Heartlands Hospital
    Birmingham, West Midlands B9 5SS, United Kingdom
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2014 to primary completion in May 2021, 87 months.

Results were first posted in May 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2013
First posted
Jul 29, 2013
StartActual
Jan 23, 2014
Primary completionActual
May 4, 2021
CompletionActual
Aug 29, 2024
Results first posted
May 26, 2022
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01909934
Lead sponsor
Takeda
Collaborators
Takeda Development Center Americas, Inc.
Responsible party
Sponsor
First posted
Jul 29, 2013
Start date
Jan 23, 2014
Primary completion
May 4, 2021
Completion
Aug 29, 2024
Results posted
May 26, 2022
Last update
Sep 19, 2025

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion